Relmada and NeurAxis Q4 Results Signal Pivotal 2026 for CNS Innovation
Key Takeaways
- Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting a strategic shift toward late-stage clinical readouts and expanded commercial coverage for CNS therapies.
- Both companies are positioning themselves as leaders in non-traditional treatments for depression and pediatric pain, respectively.
Mentioned
Key Intelligence
Key Facts
- 1Relmada is advancing REL-1017 through the Phase 3 Reliance II study for Major Depressive Disorder.
- 2NeurAxis reported expanded commercial insurance coverage for its IB-Stim pediatric neuromodulation device.
- 3Relmada has implemented stricter patient screening to reduce placebo response in clinical trials.
- 4NeurAxis is targeting functional abdominal pain in children, a market with few non-drug options.
- 5Both companies confirmed cash runways sufficient to reach major 2026 clinical and regulatory milestones.
Analysis
The fourth-quarter 2025 earnings reports from Relmada Therapeutics and NeurAxis underscore a significant transition in the central nervous system (CNS) therapeutic landscape. As the industry moves away from traditional SSRIs and opioid-based pain management, these two companies represent the dual-track progress of pharmacological innovation and neuromodulation technology. For Relmada, the focus remains squarely on the successful execution of its Phase 3 program for REL-1017, while NeurAxis is navigating the complex waters of medical device reimbursement and market penetration for its IB-Stim platform.
Relmada Therapeutics is currently at a critical juncture with its lead candidate, REL-1017 (esmethadone), an NMDA receptor antagonist designed for the adjunctive treatment of Major Depressive Disorder (MDD). Following previous setbacks in the Reliance III trial, the company has refined its clinical strategy, focusing on the ongoing Reliance II and Reliance-OLS (long-term safety) studies. CEO Sergio Traversa emphasized during the call that the company has implemented more rigorous screening processes to mitigate the high placebo response rates that have historically plagued depression trials. This strategic pivot is essential for Relmada, as the MDD market is increasingly crowded with rapid-acting antidepressants like Spravato and Auvelity. The company’s ability to demonstrate a superior safety profile and sustained efficacy will be the primary driver of its valuation heading into 2026.
For Relmada, the focus remains squarely on the successful execution of its Phase 3 program for REL-1017, while NeurAxis is navigating the complex waters of medical device reimbursement and market penetration for its IB-Stim platform.
Financially, Relmada appears to have managed its burn rate effectively, providing a cash runway that extends through key clinical milestones. This is a vital metric for biotech investors who have become increasingly risk-averse in the current high-interest-rate environment. The company’s focus on esmethadone—a molecule that lacks the dissociative side effects of ketamine—positions it as a potentially more accessible option for community-based psychiatric care. If the Reliance II data, expected in the coming year, meets its primary endpoints, Relmada could transition from a clinical-stage R&D firm to a commercial-stage powerhouse in the multi-billion dollar depression market.
What to Watch
Simultaneously, NeurAxis is demonstrating the growing viability of neuromodulation in the pediatric space. Its IB-Stim device, which uses percutaneous electrical nerve field stimulation (PENFS) to treat functional abdominal pain associated with irritable bowel syndrome (IBS), represents a shift toward non-pharmacological interventions. The Q4 2025 call highlighted the company's progress in securing commercial insurance coverage, a traditional bottleneck for medical device startups. By moving from a 'cash-pay' or 'exception-only' model to broad-based coverage, NeurAxis is lowering the barrier to entry for pediatric gastroenterologists who are often hesitant to prescribe devices without clear reimbursement pathways.
The broader implication for the Health IT and MedTech sectors is the increasing integration of digital health and device data into the clinical workflow. NeurAxis’s success depends not just on the efficacy of IB-Stim, but on the ability of providers to track patient outcomes and justify the cost-benefit ratio to payers. This mirrors a trend across the CNS sector where 'precision psychiatry'—using data to match the right patient with the right treatment—is becoming the gold standard. As both Relmada and NeurAxis move toward their next phases of growth, the market will be watching for consistency in clinical data and the ability to scale operations in an increasingly competitive neurological healthcare environment. The coming year will likely define whether these novel approaches can achieve the commercial scale necessary to disrupt established treatment paradigms.
Sources
Sources
Based on 3 source articles- seekingalpha.comRelmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call TranscriptMar 20, 2026
- insidermonkey.comRelmada Therapeutics , Inc . ( NASDAQ : RLMD ) Q4 2025 Earnings Call TranscriptMar 20, 2026
- insidermonkey.comNeurAxis , Inc . ( AMEX : NRXS ) Q4 2025 Earnings Call TranscriptMar 20, 2026
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |